Loxo Oncology Announces Submission of European Marketing Authorization Application for Larotrectinib
STAMFORD, Conn., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company developing highly selective medicines for patients with genomically defined cancers, today announced that its collaboration partner, Bayer, …